长春瑞滨联合顺铂治疗晚期乳腺癌的疗效和安全性观察

Clinical efficacy and safety of navelbine combined with cisplatin on the advanced breast cancer

目的:探讨长春瑞滨联合顺铂治疗乳腺癌肺转移的临床疗效与毒副反应。方法:对2012年7月至2016年5月我院收治的45例经蒽环类和/或紫杉类化疗后肺转移的乳腺癌患者的临床资料进行回顾性分析,分析出现肺转移后使用长春瑞滨联合顺铂治疗的临床疗效及不良反应。结果:完全缓解7例,部分缓解18例,稳定9例,进展11例,总有效率为55.6%(25/45),疾病控制率为75.6%(34/45)。中性粒细胞减少、贫血、恶心呕吐、血小板减少、肝功能损害及神经毒性的发生率分别为:46.7%、48.9%、77.8%、24.4%、44.4%、24.4%。结论:乳腺癌合并肺转移患者,采用长春瑞滨联合顺铂治疗具有良好的效果,且毒副反应相对较轻,患者可耐受,临床效果显著,值得推广和应用。

Objective:To investigate the clinical efficacy and safety of Navelbine combined with Cisplatin on the breast cancer patients with lung metastasis.Methods:The clinical data of 45 advanced breast cancer patients from July 2012 to May 2016 in our hospital with anthracycline and taxane refractory were analyzed retrospectively to analyze the clinical efficacy and safety of Navelbine combined with Cisplatin on the breast cancer patients with lung metastasis.Result:Among the 45 patients,7 patients achieved complete response(CR),18 patients achieved partial response(PR),9 patients had stable disease(SD),11 patients had progressive disease(PD).The total effective rate was 55.6%,and the disease control rate was 75.6%.The incidence rate of neutropenia reducing,anemia,vomiting,plaque decreasing,liver damage and neurotoxicity were 46.7%,48.9%,77.8%,24.4%,44.4%,and 24.4%.Conclusion:Navelbine combined with Cisplatin have better clinical efficacy on the treatment of advanced breast cancer with less adverse reactions.And worth popularizing and applying.